Skip to main content
SpringerLink
Log in
Book cover

Healthy Aging pp 201–212Cite as

Endocrine Health and Healthy Aging

  • Chapter
  • First Online:

  • 2111 Accesses

Abstract

Aging is a heterogeneous process influenced by a variety of factors, including genetics, epigenetics, environmental exposure, and lifestyle. It is associated with numerous subtle, progressive, and predictable changes that affect the endocrine system, leading to an increased susceptibility to numerous diseases. These include disorders of glucose metabolism, thyroid and parathyroid axis, sex hormone levels, and growth hormone levels. Optimization of physiological function throughout the life span is an effective strategy to increase health span. Primary, secondary, and tertiary prevention strategies related to endocrine function can delay and modify the impact of endocrine-related chronic diseases and promote healthy aging.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Veldhuis JD. Changes in pituitary function with ageing and implications for patient care. Nat Rev Endocrinol. 2013;9(4):205–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. American Diabetes Association. 11. Older adults. Diabetes Care. 2017;40(Suppl 1):S99–S104.

    Article  Google Scholar 

  3. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes. 2012;61(6):1315–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chatterjee S, Peters SA, Woodward M, Mejia Arango S, Batty GD, Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39(2):300–7.

    CAS  PubMed  Google Scholar 

  6. Ma RC. Genetics of cardiovascular and renal complications in diabetes. J Diabetes Investig. 2016;7(2):139–54.

    Article  CAS  PubMed  Google Scholar 

  7. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.

    Article  CAS  Google Scholar 

  8. Kim CH, Kim HK, Kim EH, Bae SJ, Park JY. Association between changes in body composition and risk of developing type 2 diabetes in Koreans. Diabet Med. 2014;31(11):1393–8.

    Article  PubMed  Google Scholar 

  9. Sepe A, Tchkonia T, Thomou T, Zamboni M, Kirkland JL. Aging and regional differences in fat cell progenitors – a mini-review. Gerontology. 2011;57(1):66–75.

    Article  PubMed  Google Scholar 

  10. Fink RI, Kolterman OG, Griffin J, Olefsky JM. Mechanisms of insulin resistance in aging. J Clin Invest. 1983;71(6):1523–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9.

    Article  PubMed  Google Scholar 

  12. Barzilai N, Ferrucci L. Insulin resistance and aging: a cause or a protective response? J Gerontol A Biol Sci Med Sci. 2012;67(12):1329–31.

    Article  PubMed  Google Scholar 

  13. Hoehn KL, Salmon AB, Hohnen-Behrens C, Turner N, Hoy AJ, Maghzal GJ, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci U S A. 2009;106(42):17787–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science. 2003;299(5611):1346–51.

    Article  CAS  PubMed  Google Scholar 

  15. Paolisso G, Gambardella A, Ammendola S, D’Amore A, Balbi V, Varricchio M, et al. Glucose tolerance and insulin action in healthy centenarians. Am J Physiol. 1996;270(5 Pt 1):E890–4.

    CAS  PubMed  Google Scholar 

  16. Paolisso G, Tagliamonte MR, Rizzo MR, Giugliano D. Advancing age and insulin resistance: new facts about an ancient history. Eur J Clin Invest. 1999;29(9):758–69.

    Article  CAS  PubMed  Google Scholar 

  17. Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endocrinol Metab. 2003;284(1):E7–12.

    Article  CAS  PubMed  Google Scholar 

  18. Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(26):40767–80.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Tanaka H, Seals DR. Endurance exercise performance in Masters athletes: age-associated changes and underlying physiological mechanisms. J Physiol. 2008;586(1):55–63.

    Article  CAS  PubMed  Google Scholar 

  21. Booth FW, Laye MJ, Roberts MD. Lifetime sedentary living accelerates some aspects of secondary aging. J Appl Physiol (1985). 2011;111(5):1497–504.

    Article  Google Scholar 

  22. Vogel T, Brechat PH, Lepretre PM, Kaltenbach G, Berthel M, Lonsdorfer J. Health benefits of physical activity in older patients: a review. Int J Clin Pract. 2009;63(2):303–20.

    Article  CAS  PubMed  Google Scholar 

  23. Paterson DH, Warburton DE. Physical activity and functional limitations in older adults: a systematic review related to Canada’s Physical Activity Guidelines. Int J Behav Nutr Phys Act. 2010;7:38.

    Article  PubMed  PubMed Central  Google Scholar 

  24. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. 1999;22(4):623–34.

    Article  Google Scholar 

  25. Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res Rev. 2012;11(3):390–8.

    Article  PubMed  Google Scholar 

  26. McCay CM, Crowell MF, Maynard LA. The effect of retarded growth upon the length of life span and upon the ultimate body size. 1935. Nutrition. 1989;5(3):155–71; discussion 72.

    CAS  PubMed  Google Scholar 

  27. Lane MA, Roth GS, Ingram DK. Caloric restriction mimetics: a novel approach for biogerontology. Methods Mol Biol. 2007;371:143–9.

    Article  CAS  PubMed  Google Scholar 

  28. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127(6):1109–22.

    Article  CAS  PubMed  Google Scholar 

  29. Hubbard BP, Sinclair DA. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci. 2014;35(3):146–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Anisimov VN, Semenchenko AV, Yashin AI. Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology. 2003;4(5):297–307.

    Article  CAS  PubMed  Google Scholar 

  31. De Souza A, Khawaja KI, Masud F, Saif MW. Metformin and pancreatic cancer: is there a role? Cancer Chemother Pharmacol. 2016;77(2):235–42.

    Article  PubMed  CAS  Google Scholar 

  32. Yaffe K, Falvey C, Hamilton N, Schwartz AV, Simonsick EM, Satterfield S, et al. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol. 2012;69(9):1170–5.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10(11):969–77.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.

    Article  CAS  PubMed  Google Scholar 

  35. Standards of Medical Care in Diabetes-2017: summary of revisions. Diabetes Care. 2017;40(Suppl 1):S4, S5.

    Google Scholar 

  36. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–75.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–76.

    Article  CAS  PubMed  Google Scholar 

  38. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, et al. Association between Sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(2):126–35.

    Article  PubMed  Google Scholar 

  39. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376(23):2300–2.

    Article  PubMed  Google Scholar 

  41. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

    Article  CAS  PubMed  Google Scholar 

  42. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

    Article  CAS  PubMed  Google Scholar 

  43. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–96.

    Article  CAS  PubMed  Google Scholar 

  44. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71.

    Article  CAS  PubMed  Google Scholar 

  45. Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab. 2010;12(8):716–21.

    Article  CAS  PubMed  Google Scholar 

  46. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–65.

    Google Scholar 

  47. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.

    Article  Google Scholar 

  48. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–99.

    Article  CAS  PubMed  Google Scholar 

  49. Vadiveloo T, Donnan PT, Murphy MJ, Leese GP. Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the Thyroid Epidemiology, Audit, and Research Study (TEARS). J Clin Endocrinol Metab. 2013;98(3):1147–53.

    Article  CAS  PubMed  Google Scholar 

  50. O’Leary PC, Feddema PH, Michelangeli VP, Leedman PJ, Chew GT, Knuiman M, et al. Investigations of thyroid hormones and antibodies based on a community health survey: the Busselton thyroid study. Clin Endocrinol (Oxf). 2006;64(1):97–104.

    Article  CAS  Google Scholar 

  51. Surks MI, Boucai L. Age- and race-based serum thyrotropin reference limits. J Clin Endocrinol Metab. 2010;95(2):496–502.

    Article  CAS  PubMed  Google Scholar 

  52. Boucai L, Hollowell JG, Surks MI. An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid. 2011;21(1):5–11.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Mariotti S, Franceschi C, Cossarizza A, Pinchera A. The aging thyroid. Endocr Rev. 1995;16(6):686–715.

    Article  CAS  PubMed  Google Scholar 

  54. Waring AC, Arnold AM, Newman AB, Buzkova P, Hirsch C, Cappola AR. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab. 2012;97(11):3944–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Bremner AP, Feddema P, Leedman PJ, Brown SJ, Beilby JP, Lim EM, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab. 2012;97(5):1554–62.

    Article  CAS  PubMed  Google Scholar 

  56. Silvestri E, Lombardi A, de Lange P, Schiavo L, Lanni A, Goglia F, et al. Age-related changes in renal and hepatic cellular mechanisms associated with variations in rat serum thyroid hormone levels. Am J Physiol Endocrinol Metab. 2008;294(6):E1160–8.

    Article  CAS  PubMed  Google Scholar 

  57. Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med. 1995;333(25):1688–94.

    Article  CAS  PubMed  Google Scholar 

  58. Peeters RP. Thyroid hormones and aging. Hormones (Athens). 2008;7(1):28–35.

    Article  Google Scholar 

  59. Bensenor IM, Goulart AC, Lotufo PA, Menezes PR, Scazufca M. Prevalence of thyroid disorders among older people: results from the Sao Paulo Ageing & Health Study. Cad Saude Publica. 2011;27(1):155–61.

    Article  PubMed  Google Scholar 

  60. Parle J, Roberts L, Wilson S, Pattison H, Roalfe A, Haque MS, et al. A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. J Clin Endocrinol Metab. 2010;95(8):3623–32.

    Article  CAS  PubMed  Google Scholar 

  61. Rugge JB, Bougatsos C, Chou R. Screening for and treatment of thyroid dysfunction: an evidence review for the US Preventive Services Task Force. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville (MD)2014.

    Google Scholar 

  62. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988–1028.

    Article  PubMed  Google Scholar 

  63. Ashizawa K, Imaizumi M, Usa T, Tominaga T, Sera N, Hida A, et al. Metabolic cardiovascular disease risk factors and their clustering in subclinical hypothyroidism. Clin Endocrinol (Oxf). 2010;72(5):689–95.

    Article  CAS  Google Scholar 

  64. By the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.

    Article  Google Scholar 

  65. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133–42.

    Article  CAS  PubMed  Google Scholar 

  66. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977;7(6):481–93.

    Article  CAS  Google Scholar 

  67. Diez JJ. Hypothyroidism in patients older than 55 years: an analysis of the etiology and assessment of the effectiveness of therapy. J Gerontol A Biol Sci Med Sci. 2002;57(5):M315–20.

    Article  PubMed  Google Scholar 

  68. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229(5):415–20.

    Article  CAS  PubMed  Google Scholar 

  69. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167(9):928–34.

    Article  CAS  PubMed  Google Scholar 

  70. Raffaelli M, Bellantone R, Princi P, De Crea C, Rossi ED, Fadda G, et al. Surgical treatment of thyroid diseases in elderly patients. Am J Surg. 2010;200(4):467–72.

    Article  PubMed  Google Scholar 

  71. Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab. 2011;96(1):E1–8.

    Article  CAS  PubMed  Google Scholar 

  72. Pearce SH, Razvi S, Yadegarfar ME, Martin-Ruiz C, Kingston A, Collerton J, et al. Serum thyroid function, mortality and disability in advanced old age: the Newcastle 85+ study. J Clin Endocrinol Metab. 2016;101(11):4385–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292(21):2591–9.

    Article  CAS  PubMed  Google Scholar 

  74. Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I. Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab. 2009;94(4):1251–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedus L, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules – 2016 update. Endocr Pract. 2016;22(5):622–39.

    PubMed  Google Scholar 

  76. Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1092–100.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Park HS, Roman SA, Sosa JA. Treatment patterns of aging Americans with differentiated thyroid cancer. Cancer. 2010;116(1):20–30.

    PubMed  Google Scholar 

  78. Pepe J, Romagnoli E, Nofroni I, Pacitti MT, De Geronimo S, Letizia C, et al. Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos Int. 2005;16(7):805–12.

    Article  CAS  PubMed  Google Scholar 

  79. Serdar MA, Batu Can B, Kilercik M, Durer ZA, Aksungar FB, Serteser M, et al. Analysis of changes in parathyroid hormone and 25 (OH) vitamin D levels with respect to age, gender and season: a data mining study. J Med Biochem. 2017;36(1):73–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Need AG, O’Loughlin PD, Morris HA, Horowitz M, Nordin BE. The effects of age and other variables on serum parathyroid hormone in postmenopausal women attending an osteoporosis center. J Clin Endocrinol Metab. 2004;89(4):1646–9.

    Article  CAS  PubMed  Google Scholar 

  81. Bjorkman M, Sorva A, Tilvis R. Parathyroid hormone as a mortality predictor in frail aged inpatients. Gerontology. 2009;55(6):601–6.

    Article  PubMed  CAS  Google Scholar 

  82. Sambrook PN, Chen JS, March LM, Cameron ID, Cumming RG, Lord SR, et al. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin d status, bone mass, and renal function in the frail and very old: a cohort study. J Clin Endocrinol Metab. 2004;89(11):5477–81.

    Article  CAS  PubMed  Google Scholar 

  83. Buchebner D, Malmgren L, Christensson A, McGuigan F, Gerdhem P, Ridderstrale M, et al. Longitudinal assessment of PTH in community-dwelling older women-elevations are not associated with mortality. J Endocr Soc. 2017;1(6):615–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. El Hilali J, de Koning EJ, van Ballegooijen AJ, Lips P, Sohl E, van Marwijk HWJ, et al. Vitamin D, PTH and the risk of overall and disease-specific mortality: results of the longitudinal aging study Amsterdam. J Steroid Biochem Mol Biol. 2016;164:386–94.

    Article  PubMed  CAS  Google Scholar 

  85. Bansal N, Zelnick L, Robinson-Cohen C, Hoofnagle AN, Ix JH, Lima JA, et al. Serum parathyroid hormone and 25-hydroxyvitamin D concentrations and risk of incident heart failure: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2014;3(6):e001278.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Melton LJ 3rd. Epidemiology of primary hyperparathyroidism. J Bone Miner Res. 1991;6(Suppl 2):S25–30; discussion S1–2.

    PubMed  Google Scholar 

  87. Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Heath H 3rd. Risk of age-related fractures in patients with primary hyperparathyroidism. Arch Intern Med. 1992;152(11):2269–73.

    Article  PubMed  Google Scholar 

  88. Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O’Fallon W, Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14(10):1700–7.

    Article  CAS  PubMed  Google Scholar 

  89. Prete C, Foppiani L, Trasciatti S, Senesi B, Veneziano M, Barone A, et al. Primary hyperparathyroidism and neuropsychiatric alterations in a nonagenarian woman. Aging Clin Exp Res. 2005;17(1):67–70.

    Article  PubMed  Google Scholar 

  90. Paslakis G, Gilles M, Frankhauser P, Lanczik O, Deuschle M, Frolich L, et al. Two cases of primary hyperparathyroidism with depressive and cognitive symptoms. J Nutr Health Aging. 2010;14(9):798–9.

    Article  CAS  PubMed  Google Scholar 

  91. Fui SL, Bonnichon P, Bonni N, Delbot T, Andre JP, Pion-Graff J, et al. Hyperparathyroidism in octogenarians: a plea for ambulatory minimally invasive surgery under local anesthesia. Ann Endocrinol (Paris). 2016;77(5):600–5.

    Article  Google Scholar 

  92. Sonntag WE, Steger RW, Forman LJ, Meites J. Decreased pulsatile release of growth hormone in old male rats. Endocrinology. 1980;107(6):1875–9.

    Article  CAS  PubMed  Google Scholar 

  93. Toogood AA, O’Neill PA, Shalet SM. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab. 1996;81(2):460–5.

    CAS  PubMed  Google Scholar 

  94. Weltman A, Weltman JY, Hartman ML, Abbott RD, Rogol AD, Evans WS, et al. Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: effects of gender. J Clin Endocrinol Metab. 1994;78(3):543–8.

    CAS  PubMed  Google Scholar 

  95. Veldhuis JD, Roelfsema F, Keenan DM, Pincus S. Gender, age, body mass index, and IGF-I individually and jointly determine distinct GH dynamics: analyses in one hundred healthy adults. J Clin Endocrinol Metab. 2011;96(1):115–21.

    Article  CAS  PubMed  Google Scholar 

  96. Veldhuis JD, Iranmanesh A, Weltman A. Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans. Endocrine. 1997;7(1):41–8.

    Article  CAS  PubMed  Google Scholar 

  97. Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS, et al. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab. 2003;88(8):3664–7.

    Article  CAS  PubMed  Google Scholar 

  98. Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne). 2013;4:64.

    Article  Google Scholar 

  99. Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks JB, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab. 2002;87(12):5649–57.

    Article  CAS  PubMed  Google Scholar 

  100. Blackman MR, Sorkin JD, Munzer T, Bellantoni MF, Busby-Whitehead J, Stevens TE, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA. 2002;288(18):2282–92.

    Article  CAS  PubMed  Google Scholar 

  101. Borst SE. Interventions for sarcopenia and muscle weakness in older people. Age Ageing. 2004;33(6):548–55.

    Article  PubMed  Google Scholar 

  102. Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104–15.

    Article  PubMed  Google Scholar 

  103. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420–9.

    Article  PubMed  PubMed Central  Google Scholar 

  104. White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009;94(4):1198–206.

    Article  CAS  PubMed  Google Scholar 

  105. Berryman DE, Christiansen JS, Johannsson G, Thorner MO, Kopchick JJ. Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm IGF Res. 2008;18(6):455–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of A. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–31.

    Article  CAS  PubMed  Google Scholar 

  107. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715.

    Article  PubMed  Google Scholar 

  108. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Vigen R, O’Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36.

    Article  CAS  PubMed  Google Scholar 

  110. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-Normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–81.

    Article  CAS  PubMed  Google Scholar 

  112. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail. 2012;5(3):315–21.

    Article  CAS  PubMed  Google Scholar 

  113. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Lessons from the testosterone trials. Endocr Rev. 2018;39:369–86.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, Bhasin S, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317(7):708–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728–53.

    Article  Google Scholar 

  116. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202–16.

    Google Scholar 

  117. ACOG Committee Opinion No. 565: hormone therapy and heart disease. Obstet Gynecol. 2013;121(6):1407–10.

    Google Scholar 

  118. Ohlsson C, Vandenput L, Tivesten A. DHEA and mortality: what is the nature of the association? J Steroid Biochem Mol Biol. 2015;145:248–53.

    Article  CAS  PubMed  Google Scholar 

  119. Kenny AM, Boxer RS, Kleppinger A, Brindisi J, Feinn R, Burleson JA. Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. J Am Geriatr Soc. 2010;58(9):1707–14.

    Article  PubMed  Google Scholar 

  120. Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, Scott SM, et al. Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab. 2006;91(8):2986–93.

    Article  CAS  PubMed  Google Scholar 

  121. Jankowski CM, Gozansky WS, Kittelson JM, Van Pelt RE, Schwartz RS, Kohrt WM. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endocrinol Metab. 2008;93(12):4767–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Medicine, University of Connecticut School of Medicine, Farmington, CT, USA

    Faryal S. Mirza, Pamela Taxel & Pooja Luthra

Authors
  1. Faryal S. Mirza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pamela Taxel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pooja Luthra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pooja Luthra .

Editor information

Editors and Affiliations

  1. Center on Aging and Departments of Family Medicine and Medicine, University of Connecticut School of Medicine, Farmington, CT, USA

    Patrick P. Coll

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mirza, F.S., Taxel, P., Luthra, P. (2019). Endocrine Health and Healthy Aging. In: Coll, P. (eds) Healthy Aging. Springer, Cham. https://doi.org/10.1007/978-3-030-06200-2_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-06200-2_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-06199-9

  • Online ISBN: 978-3-030-06200-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation